July 7, 2022

Highlights
• According to Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, the FDA took a great decision

In an attempt to safeguard teenagers from the dreadful COVID-19, the U.S. Food and Drug Administration (FDA) on Thursday has granted approval to the emergency use of Pfizer’s COVID-19 booster shots for US citizens ageing between 16 and 17. The country of the US has reported few cases of Omicron variant of the coronavirus.

In a press release, Acting FDA Commissioner Dr. Janet Woodcock said that vaccination and getting a booster when eligible, along with other preventive measures like masking and avoiding large crowds and poorly ventilated spaces, remain our most effective methods for fighting COVID-19. He further said that as people gather indoors with family and friends for the holidays, they can’t let up on all the preventive public health measures that we have been taking during the pandemic. Dr. Woodcock also said that with both the Delta and Omicron variants continuing to spread, vaccination remains the best protection against COVID-19.

On the other hand, according to Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, the FDA took a great decision.